www.hcvadvocate.org new topics

[Guest guest]

The following items have just been posted to our siteswww.hcvadvocate.org and www.hbvadvocate.orgHepatitis Cwww.hcvadvocate.org **AASLD 2005 Coveragehttp://www.hcvadvocate.org/news/reports/AASLD_2005/TOC_AASLD_2005_HCV.htm*Drugs in Development *Drugs in Development - Preclinical *Drugs in Development - Phase 3.4 Trials *HCV Medications Approved by the FDA *Treatment Issues*Diagnosis and Natural History*Diagnostic Tools*Epidemiology*HIV/HCV Coinfection**A Final Word on Medicare Prescription Drug Benefits http://www.hcvadvocate.org/hepatitis/hepC/Medicare_Drug_Plan_Finalword.htm**HCV ADVOCATE WEEKLY NEWS REVIEW: A Review of HCV, HBV and HIV/HCV Coinfection Related News and Highlights--Week Ending: November 12th, 2005http://www.hcvadvocate.org/news/newsRev/2005/NewsRev-126.htmlIn this Issue:• Seale Success Supports Need for Organ Donors • Data on Schering-Plough's Oral HCV Protease Inhibitor to Be Presented for First Time at American Association for the Study of Liver Diseases (AASLD) Meeting • Job Helps Eileen Cope with Hepatitis • Hepatitis C Often Untreated and Outcomes Lag behind Trials in Clinical Practice: Presented at ACG • iQur Ltd Closes B#2.6 Million Investment, Wins Major DoH Award for Healthcare New Hampshire Public Radio Series Examines 'Building Wave' of Hepatitis C in State • New Hampshire Public Radio Series Examines 'Building Wave' of Hepatitis C in State• Health Care Workers Want Safety Needles Made Mandatory in British Columbia • Veterans at Risk: Hepatitis C Still Serious Risk • ViroPharma Announces that Treatment with HCV-796 Reduces Hepatitis C Virus Levels • Alcohol Use Progresses Hep C-Related Cirrhosis • Preventing Hemodialysis after Liver Transplant • AASLD Issues Call for Americans to Fight Liver Disease as Screening Reveals Alarmingly High Prevalence of Hepatitis B Among Asian Americans • Ascites Impairs Gastric Function in Cirrhosis • Vertex Applies to Take Hepatitis C Drug to Phase II Trials • Major Milestone Reached in Hepatitis C Vaccine Program • New Studies with Pegasys plus Copegus in Hepatitis C Treatment to be Presented at AASLD Annual Meeting • Cambridge Biotech Develops Hepatitis C Pill • Pine Man Alerts Rim Country Residents about Hepatitis C • Valopicitabine (NM283) Combined with Pegylated Interferon Demonstrated Significantly Greater Suppression of Hepatitis C Virus (HCV) Replication in Treatment-Refractory Patients Compared to Retreatment with Ribavirin Plus Pegylated Interferon • Calif. Liver Program Closed after Decertification• Peg-Intron® and Rebetol® Combination Therapy Demonstrates Consistently High Response Rates across Patient Weight Groups in “Real-Life” Treatment Setting Hepatitis Bwww.hbvadvocate.org**AASLD 2005 Hepatitis B coveragehttp://www.hbvadvocate.org/news/reports/HBV_AASLD_2005/TOC_AASLD_2005_HBV.htm**Russian Easy B Factsheetshttp://www.hbvadvocate.org/hepatitis/factsheets.asp#RussianB